Childrens Hospital London Health Sciences Centre

London, Ontario N6A5W9

2 studies enrolling now · 12 studies all time

What they study most

Achondroplasia, Acute Lymphoblastic Leukemia, Angelman Syndrome, Duchenne Muscular Dystrophy, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Low Grade Glioma, Low-grade Glioma, Lymphoma, Muscular Diseases, Muscular Disorders, Atrophic, Muscular Dystrophies

Studies at this site

• Long-term Extension of GTX-102 in Angelman Syndrome — Enrolling by invitation
• Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy — Running, not enrolling
• DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) — Running, not enrolling
• Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy — Completed
• Extension Study of Infigratinib in Children With Achondroplasia (ACH) — Enrolling by invitation
• Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) — Running, not enrolling
• Finding the Optimum Regimen for Duchenne Muscular Dystrophy — Completed
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase — Completed
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) — Completed
• A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy — Stopped early
• An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy — Stopped early
• A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects — Stopped early